Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0790
    -0.0003 (-0.03%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2615
    -0.0007 (-0.05%)
     
  • USD/JPY

    151.3300
    -0.0420 (-0.03%)
     
  • Bitcoin USD

    70,163.93
    -483.20 (-0.68%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Axsome Therapeutics: Teaching Old Drugs New Tricks

Brean Capital assumed coverage of Axsome Therapeutics Inc (NASDAQ: AXSM) with a Buy rating and $20 target price, implying a potential upside of 154 percent.

The company's leading product candidate is AXS-02, a non-opioid therapeutic in development for chronic pain. AXS-02 is being studied for complex regional pain syndrome (CRPS), knee osteoarthritis (OA) with bone marrow lesions (BMLs), and chronic lower back pain (CLBP) with modic changes (MC).

Meanwhile, Axsome's other product candidate, AXS-05, is in trials indicated for treatment resistant depression (TRD) and agitation in Alzheimer's disease (AD). AXS-05 is a fixed-dose combination of dextromethorphan and bupropion, which have been shown to be effective in activating central nervous system receptors.

"We believe the synergistic effects provided by the combination will be superior to either single agent in TRD and AD, as they have differing mechanisms of action," analyst Difei Yang wrote in a note.

Yang says the company has the following upcoming catalysts:

  • "AXS-02 vs. CRPS Phase III trial (CREATE-1) interim analysis in 4Q16";

  • "IND filing for AXS-05 vs. AD Phase II/III in 4Q16"; and

  • "CREATE-1 trial completion by YE2017."

"We see the value drivers, CPRS, TRD, and AD, possessing lower-than-average R&D risks and a proven business model that lends itself to a shorter line to commercialization," Yang added.

Latest Ratings for AXSM

Oct 2016

Brean Capital

Assumes

Buy

Dec 2015

Brean Capital

Initiates Coverage on

Buy

View More Analyst Ratings for AXSM
View the Latest Analyst Ratings

See more from Benzinga

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement